Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Eyeview, Which Turns a Single Video Ad Into Thousands of Video Ads, Raises More Money

Marker LLC puts $15 million into the ad tech startup.

Peter Kafka
Peter Kafka covered media and technology, and their intersection, at Vox. Many of his stories can be found in his Kafka on Media newsletter, and he also hosts the Recode Media podcast.

A big reason that advertisers like TV is its mass reach — you buy one ad, on one network, and you can reach millions of people.

And a big reason advertisers like the Internet is because of its specificity — in theory, you pluck a single person out of the Web and deliver a message tailored just for him or her.

Oren Harnevo says he can combine the two ideas.

His Eyeview startup promises marketers that it can create dozens, or tens of thousands, of versions of a single video ad — and pick the right one to show a Web surfer, in real time. There are a bunch of companies that do something similar with conventional display ads, but Harnevo says it’s hard to translate that idea into video.

Investors seem to like the pitch. Over the last six years, Harnevo has raised $19.5 million. Now he’s adding another $15 million, all of which comes from Marker LLC, which had already backed the company.

Marker seems to like investing in Israeli tech founders, like Harnevo, who have migrated to New York; other companies in its portfolio that fit that description include Taboola, Wochit and Interlude.

Harnevo says the new money will go into tech that will help automate his product as well as add more sales and marketing help. He has also hired West Naze, a longtime News Corp. executive, to help on the sales side.

Here’s a brief demo video that shows off the kind of custom work Eyeview can do. Eyeview doesn’t create the ads, but creates custom animations that can have thousands of different versions. All of those get stored in the cloud, and then are shown to different Web users, at different times, depending on who they are and what they’re doing.

http://youtu.be/ul6aLgzQXUo

And if Harnevo’s name sounds familiar, there’s a good reason for that: His older brother is Ran Harnevo, who built 5Min, another video ad tech company, then sold it to AOL, and stayed there until a few weeks ago.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh